A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence
Public ClinicalTrials.gov record NCT04298606. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 0 Study of CIMAvax-EGF Vaccine in Patients Who Are at High Risk for Lung Cancer and Lung Cancer Survivors at Risk for Recurrence
Study identification
- NCT ID
- NCT04298606
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Early Phase 1
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Enrollment
- 20 participants
Conditions and interventions
Conditions
Interventions
- Quality-of-Life Assessment Other
- Questionnaire Administration Other
- Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine Biological
Other · Biological
Eligibility (public fields only)
- Age range
- 50 Years to 79 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 21, 2021
- Primary completion
- Dec 4, 2025
- Completion
- Feb 5, 2026
- Last update posted
- Mar 16, 2026
2021 – 2026
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04298606, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 16, 2026 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04298606 live on ClinicalTrials.gov.